[Brussels, 20th June 2025] – According to Clearview Market Insights (CVMI), the clinical trials market in Europe is projected to expand from USD 16.5 billion in 2024 to USD 25.8 billion by 2031, driven by regulatory reform, digital transformation, and a focus on rare diseases.

"Europe is becoming a globally attractive hub for multicountry trials and digital-first trial designs," said Dr. Helena Vos, CVMI’s Director of Clinical Research Strategy.

Explore interactive dashboards and country-specific trial data at: https://clearviewmarketinsights.com/report-details/europe-clinical-trials-market/

Growth Catalysts:

• Oncology and rare disease trials growing at 8–10% annually
• Remote patient monitoring and ePRO platforms accelerating Phase III studies
• EU-CTR creating a harmonized framework for trial approval across 27 countries

Digital Transformation:

ICON and IQVIA are expanding GDPR-compliant eClinical platforms, featuring tools that consolidate patient recruitment, remote consent, and site monitoring into unified dashboards. These advancements are decreasing startup timelines by 25–30% in multi-country trials.

Decentralized and Hybrid Trial Uptake:

More than 50% of newly initiated trials in France, the UK, and the Nordics use hybrid models. Wearables and virtual consultations are incorporated across cardiovascular, neurology, and endocrinology studies.

Country Highlights:

Germany and the Netherlands continue to lead in academic trial sponsorship. Eastern Europe is emerging as a recruitment hub due to its high patient availability and low dropout rates. Scandinavian countries are making progress in regulatory alignment with the EU CTR and are supporting remote-first designs.

Public-Private Collaboration:

European consortia, such as ECRIN and IMI, are facilitating pan-European trials with standardized protocols. EUPATI involves patients early in the design of oncology and neurodegenerative trials.

Future Outlook:

By 2031, more than 55% of trials initiated in Europe will be hybrid or fully decentralized. AI-driven protocol design, multilingual eConsent, and real-time data visibility will become industry standards. Public health priorities—such as antimicrobial resistance and long COVID—are also driving new trial streams.

For more insights, visit https://clearviewmarketinsights.com/

About Clearview Market Insights:

Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.

Media contact:

Bhavani K

Marketing and Sales Head

ClearView Market Insights

Mail: sales@clearviewmarketinsights.com

Phone: +1 917-993-7369